Financial toxicity — the economic hardship caused by treatment itself — has become a side effect as relevant as the clinical ones, and radiation oncology is starting to address it with concrete solutions at the bedside. The central message of a discussion led by the American Society for Radiation Oncology (ASTRO) is that there is much to do at every level of the health system.
What financial toxicity is
The term describes the economic difficulties that fall on patients because of their medical needs. As the costs of diagnosis, treatment and survivorship rise, this burden grows — and it is not limited to the hospital bill. It includes daily transportation, lost income, supportive care and indirect expenses that pile up over weeks of therapy. In cancer, where treatment is long and intensive, the impact is especially heavy.
The problem is not only financial: patients under economic stress adhere less to treatment, delay exams and report worse quality of life. In other words, financial toxicity contaminates clinical outcomes themselves.
Solutions at the patient and provider level
The good news is that some answers are within reach of the care team. Talking openly about costs with the patient — rather than treating the subject as taboo — already changes decisions. Offering financial navigation services, which help patients understand coverage, benefits and available assistance, is one of the highest-impact measures.
Another lever is the therapeutic choice itself. Alternative schedules, such as hypofractionation (delivering the dose in fewer sessions), reduce travel and time off work without compromising the oncologic result in many indications. Precision radiotherapy, as we saw when covering 4D MR technologies applied to radiation therapy, points in that direction: treating better, in less time.
The revealing case of parking
A concrete example shows how small barriers become large obstacles: one-third of NCI-designated cancer centers in the United States charge patients for parking while they receive radiation therapy — treatment that is typically daily, for several weeks. For the most vulnerable patient, that recurring charge can be the difference between completing or abandoning treatment.
Practical solutions such as subsidized parking or vouchers directly improve access and affordability. These are low-cost interventions for the institution with a high human return — the kind of measure that does not depend on sweeping reform to make an immediate difference.
Institutional and systemic solutions
At the institutional and system level, ASTRO has promoted initiatives such as the Choosing Wisely guidelines, which aim to increase the value of cancer care by encouraging conversations between radiation oncologists and patients to choose the best evidence-based course — and to eliminate costly tests or procedures that offer little or no benefit.
Financial toxicity is a multifactorial problem, and solutions must be pursued at all levels — patient-provider, institutional and systemic — always considering each patient’s individual and local context. The cost debate is also political: discussions about physician payment reform and billing rules, such as legislation against surprise medical bills, directly shape how much patients pay out of pocket.
How to measure financial toxicity
You cannot manage what you do not measure. Researchers have therefore developed validated instruments to quantify the problem — the best known is the COST (COmprehensive Score for financial Toxicity), a short questionnaire that captures the degree of treatment-related financial stress. Applying it at screening makes it possible to identify at-risk patients early, before they abandon treatment for lack of resources.
The logic is the same as for any other adverse effect: screen, grade and intervene. Adding a question about financial hardship to the clinical interview is cheap and can redirect the patient to financial navigation or to more affordable schedules before the financial harm sets in and starts to compound.
Implications for practice and the broader picture
Financial toxicity takes specific forms in different systems. Even with public coverage, patients often travel long distances to reach radiotherapy services concentrated in a few centers, bearing transport, food and lodging costs. A shortage of machines in some regions worsens the problem, turning logistics into a barrier as real as the direct cost.
For the service, this means measuring and confronting financial toxicity should be part of care, not an administrative footnote. Financial risk screening, structured social support and the rational use of shorter schedules are viable, immediate paths.
Outlook
Treating financial toxicity as a measurable side effect — not as the patient’s bad luck — is the key shift. When the team asks about costs, offers financial navigation, chooses efficient schedules and removes small barriers like parking, it protects both the wallet and the clinical outcome. The next frontier is embedding these indicators into routine practice and health policy, so that affordability is seen as part of the quality of care.
